Consequently, HER2 may serve as a novel therapeutic target for bladder cancer. Disitamab Vedotin (DV; RC48-ADC) is an antibody-drug conjugate (ADC) comprising a fully humanized HER2-directed monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable mc-vc linker....
15 Feb 2025Updated efficacy data from a phase II trial in Bladder cancer released by RemeGen 12 Dec 2024Efficacy and adverse events data from a phase II/III trial in Her2 positive Breast cancer released by RemeGen 31 Oct 2024CDE of China's NMPA accepts BLA for Disitamab vedotin for Breast...
Until recently, the development of novel antibody–drug conjugates (ADCs), such as trastuzumab deruxtecan (T-Dxd), disitamab vedotin (RC48), and ARX788, has revolutionized the treatment landscape of HER2 positive G/GEJ cancer. With the regulatory approval of T-Dxd for the treatment of ...
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.doi:10.1200/JCO.2025.43.5_suppl.665...
Introduction: Muscle-invasive bladder cancer (MIBC) is an aggressive bladder cancer characterized by invasion of the muscular bladder wall, often necessitating a multimodal treatment approach for optimal outcomes. This study aimed to compare the real-world efficacy and safety of di...
Muscle-invasive bladder cancer (MIBC)Bladder-sparing treatmentDisitamab VedotinToripalimabTransurethral bladder tumor resection (TURBT)Pelvic lymph node dissection (PLND)Muscle invasive bladder cancer (MIBC) is a malignancy with high recurrence and metastasis rate. Radical cystectomy and lymph node ...
2002P Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world studydoi:10.1016/j.annonc.2024.08.2088L. YanJ. HuJ. LiuJ. ChenX. Zu
bladder cancerbladder-sparing protocolimmunotherapyObjective: Our study aims to assess the effectiveness and safety profile of Disitamab Vedotin (DV, RC48-ADC), an innovative humanized anti-HER2 antibody conjugated with tubulin-disrupting antimitotic drug monomethyl auristatin E (MMAE) via a cleavable ...
Disitamab Vedotin + Toripalimab for Muscle-Invasive Bladder Cancerdoi:10.1097/01.COT.0000000000000060Catlin NalleyWolters Kluwer Health, Inc.Oncology Times
21631#Background:For HER2 positive muscle-invasive bladder cancer (MIBC), the efficacy of cisplatin-based NAC is unsatisfied, and adverse reactions are inevitable or even intolerable. Disitamab vedotin is an antibody-drug conjugate composed of an anti-HER2 antibody disitamab and MMAE payload. ...